Tetherex Pharmaceuticals Corporation: Company Profile

Background

Overview

Tetherex Pharmaceuticals Corporation is a privately held, clinical-stage biopharmaceutical company headquartered in Oklahoma City, Oklahoma. Established in 2014, the company specializes in developing novel therapeutics targeting selectin inhibitors for the treatment of a broad range of inflammatory diseases, including thrombosis, inflammatory conditions, and cancer. Additionally, Tetherex is advancing a single-cycle adenovirus vaccine platform aimed at addressing multiple infectious diseases and cancer indications.

Mission and Vision

Tetherex Pharmaceuticals is committed to pioneering innovative biopharmaceutical solutions that enhance global health by addressing unmet medical needs through the development of cutting-edge therapeutics and vaccines.

Primary Area of Focus

The company's primary focus encompasses:

Selectin Inhibitor Therapeutics: Developing inhibitors targeting selectin molecules to modulate cell adhesion, thereby treating diseases characterized by excessive inflammation and thrombosis.

Single-Cycle Adenovirus Vaccine Platform: Advancing a novel vaccine platform designed to elicit robust immune responses against infectious diseases and certain cancers.

Industry Significance

Tetherex Pharmaceuticals plays a pivotal role in the biopharmaceutical industry by introducing innovative approaches to treating complex diseases. Its focus on selectin inhibitors and advanced vaccine platforms positions the company at the forefront of therapeutic development, addressing critical areas in inflammation, thrombosis, and infectious diseases.

Key Strategic Focus

Core Objectives

Therapeutic Development: Advance selectin inhibitor therapeutics to effectively treat thrombosis, inflammatory diseases, and cancer.

Vaccine Innovation: Develop and commercialize a single-cycle adenovirus vaccine platform targeting multiple infectious diseases and cancer indications.

Specific Areas of Specialization

Selectin Inhibitors: Targeting selectin molecules to modulate cell adhesion and treat diseases with excessive inflammation and thrombosis.

Adenovirus Vaccine Platforms: Utilizing a single-cycle adenovirus platform to enhance antigen expression and immune response without generating infectious virus particles.

Key Technologies Utilized

Single-Cycle Adenovirus Platform: A novel vaccine platform developed to enhance antigen expression and immune response.

Primary Markets or Conditions Targeted

Thrombosis: Developing treatments for venous thromboembolism (VTE) and other thrombotic conditions.

Inflammatory Diseases: Addressing conditions such as Crohn's disease and other inflammatory disorders.

Infectious Diseases: Targeting diseases like COVID-19 through innovative vaccine platforms.

Financials and Funding

Funding History

Tetherex Pharmaceuticals has secured significant funding to support its research and development initiatives:

Series B Financing: In April 2018, the company completed a $50 million private placement of Series B preferred stock. The funding was led by MPM Capital and a group of Oklahoma-based investors, including Dr. Philip Jones, a member of the Tetherex Board of Directors.

Utilization of Capital

The proceeds from the Series B financing were allocated as follows:

Phase 2 Clinical Trials: Conducting trials for SelK2, a PSGL-1 inhibitor, in the treatment of venous thromboembolism (VTE) in patients undergoing total knee replacement surgery.

Inflammatory Indications: Initiating a second Phase 2 trial evaluating SelK2 in Crohn's disease or other inflammatory conditions.

Pipeline Development

Key Pipeline Candidates

SelK2: A humanized monoclonal antibody targeting PSGL-1, designed to block interactions with selectin molecules and chemokines involved in inflammatory responses.

Stages of Clinical Trials or Product Development

Phase 2 Clinical Trials: Ongoing trials for SelK2 in VTE and Crohn's disease.

Target Conditions

Venous Thromboembolism (VTE): A condition involving blood clots in veins, particularly in patients undergoing total knee replacement surgery.

Crohn's Disease: An inflammatory bowel disease characterized by chronic inflammation of the gastrointestinal tract.

Relevant Timelines for Anticipated Milestones

Phase 2 Trial Initiation: The trials for SelK2 are expected to commence later in the year following the Series B financing in April 2018.

Technological Platform and Innovation

Proprietary Technologies

Single-Cycle Adenovirus Vaccine Platform: A novel platform developed to enhance antigen expression and immune response without generating infectious virus particles.

Significant Scientific Methods

Single-Cycle Adenovirus Technology: Utilizing a single-cycle adenovirus to amplify antigen expression, leading to a robust immune response.

Leadership Team

Key Executive Profiles

Dr. Scott Rollins: Chairman and Chief Executive Officer. Dr. Rollins has been instrumental in advancing Tetherex's strategic vision and overseeing its clinical development programs.

Dr. Russell Rother: President and Chief Operating Officer. Dr. Rother has played a key role in the development of Tetherex's vaccine platform and its clinical studies.

Leadership Changes

No significant leadership changes have been reported.

Competitor Profile

Market Insights and Dynamics

The biopharmaceutical industry, particularly in the areas of selectin inhibitors and vaccine development, is characterized by rapid innovation and competition. Companies are striving to develop effective treatments for inflammatory diseases, thrombosis, and infectious diseases, with a focus on novel therapeutic approaches and vaccine platforms.

Competitor Analysis

Tetherex Pharmaceuticals faces competition from several companies in its therapeutic and vaccine development areas:

Regulus Therapeutics: Focuses on microRNA-targeted therapeutics for various diseases.

Portola Pharmaceuticals Inc.: Specializes in therapies for thrombosis and other hematologic diseases.

Momenta Pharmaceuticals, Inc.: Develops novel therapies for rare immune-mediated diseases.

Strategic Collaborations and Partnerships

Mayo Clinic: In July 2021, Tetherex signed an exclusive worldwide license agreement with Mayo Clinic for the development and commercialization of its single-cycle adenovirus vaccine platform. This collaboration aims to target multiple infectious diseases, starting with a Phase 1 clinical study for COVID-19.

Operational Insights

Tetherex Pharmaceuticals differentiates itself through its innovative approach to vaccine development and its focus on selectin inhibitors, positioning the company as a leader in addressing complex diseases with unmet medical needs.

Strategic Opportunities and Future Directions

The company's strategic roadmap includes:

Advancing Clinical Trials: Progressing SelK2 through Phase 2 trials for VTE and Crohn's disease.

Expanding Vaccine Development: Leveraging the single-cycle adenovirus platform to develop vaccines for additional infectious diseases and cancer indications.